- Multiplex assay that allows amplifying mutations W515L (NM_005373.2: c.1544G>T) and W515K (NM_005373.2: c.1543_1544delTGinsAA) in the MPL gene.
- The results obtained in this test allow to confirm the diagnosis of the patient. This assay is not optimal for the study of minimal residual disease (MRD) in AML patients.
- The detection limit has been set at 1% for each of the W515l and W515K mutations.
- Includes an endogenous control to confirm sample quality and integrity.
- It includes a positive control that simulates a heterozygous genotype, which guarantees the functionality of the PCR systems and which helps the interpretation in the qualitative analysis.
- For in vitro diagnostic use.
Are you a healthcare professional?
This content is intended exclusively for healthcare professionals.
The content is for informational purposes only and is not intended for the general public.